Thriva

Thriva, founded in 2015 and based in the United Kingdom, is innovating in the field of personalized health diagnostics. The company offers at-home health tests with GP-reviewed results and evidence-based advice, enabling users to better understand and manage their long-term health.

Aligning with its mission to help people thrive through health insights, Thriva has launched over 5 million test kits to numerous customers who seek comprehensive insight into health metrics such as nutrient levels, hormones, and cholesterol. The company continually expands its testing modalities, currently advancing clinical innovations like sexual health screens and genetic testing. This positions Thriva at the forefront of health tech innovation, creating a new category in the health market.

The company recently secured a £10.00K grant from UK Research and Innovation on 01 October 2024, underlining its potential for growth and market impact. With its dual B2C and B2B offerings, Thriva presents significant upside for investors seeking to tap into cutting-edge diagnostics and healthcare solutions. Its subscription model, offering flexible terms, promises recurrent revenue and scalability.